{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-lower-women/management/recurrent-uti-no-visible-haematuria-not-pregnant-or-catheterized/","result":{"pageContext":{"chapter":{"id":"3e093a06-3197-58a5-8c61-94586835adba","slug":"recurrent-uti-no-visible-haematuria-not-pregnant-or-catheterized","fullItemName":"Scenario: Recurrent UTI  (no visible haematuria, not pregnant or catheterized)","depth":2,"htmlHeader":"<!-- begin field 8db74a09-37ac-47bf-b4ed-a71b00f2a84d --><h2>Scenario: Suspected recurrent UTI without haematuria in women who are not catheterized or pregnant</h2><!-- end field 8db74a09-37ac-47bf-b4ed-a71b00f2a84d -->","summary":"Covers the management of recurrent UTIs that are not associated with haematuria in women who are not pregnant or catheterized. It includes recommendations on measures to prevent recurrent UTIs and when to refer to a specialist for investigation of possible underlying causes.","htmlStringContent":"<!-- begin item 10b18fbf-46c0-4e97-8ed6-a71b00f2a961 --><!-- begin field 1ab9dc81-d778-4a36-9855-acbd0084e67a --><p>From age 16 years onwards.</p><!-- end field 1ab9dc81-d778-4a36-9855-acbd0084e67a --><!-- end item 10b18fbf-46c0-4e97-8ed6-a71b00f2a961 -->","topic":{"id":"4205a2dd-1d74-53f2-90f4-5239307d2883","topicId":"7e36f7cd-e707-44db-a683-f4197a84b187","topicName":"Urinary tract infection (lower) - women","slug":"urinary-tract-infection-lower-women","lastRevised":"Last revised in October 2020","chapters":[{"id":"96f75303-a8ae-50a0-9d5c-e5a9b96e67f1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cafb451d-db29-558a-a6cc-20d82dde3df9","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"14a65465-7aa4-5024-bb53-b3b2099b526a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7b90ea0f-0f86-5457-965d-930656bd2f02","slug":"changes","fullItemName":"Changes"},{"id":"4f3fd7bc-437b-509c-9a2d-5318de2b1e8b","slug":"update","fullItemName":"Update"}]},{"id":"850e1193-41eb-50b7-b401-ac0396c6e585","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18c79474-b4ac-50cd-801a-3738d79a1159","slug":"goals","fullItemName":"Goals"},{"id":"24f4bdf7-0aa4-5f6b-a117-2c3a7da00984","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6b590746-634f-5a0c-b995-5f98bd9c6f0d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c2be4f2-9e65-53d3-8ff6-7534932e7dc6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"835cf60d-f7b4-57b8-97ee-607930381034","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a526f295-371c-52d5-bd46-93333947aade","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"28adde3c-64d3-5e21-8797-08c56ab570c5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4a732f85-1f37-5288-a872-611c3528c53e","slug":"definition","fullItemName":"Definition"},{"id":"8e922399-2c9d-5777-9660-944733f631f5","slug":"causes","fullItemName":"Causes"},{"id":"8fa46cfc-d97b-5218-847f-9553a7ce2854","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9ad7aa8-f54d-55a8-b6f1-804d616de2b4","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a176b8d4-1d8f-5f62-935e-4f6fc4696153","slug":"complications","fullItemName":"Complications"}]},{"id":"03286f6f-e3d8-5889-8453-1db9ffb07914","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ec9700ef-7ba2-524e-868a-3dc60b345625","slug":"when-to-suspect-uti","fullItemName":"When to suspect UTI"},{"id":"182ae581-d75a-507d-8146-e0d7d26dcad8","slug":"assessment","fullItemName":"Assessment"},{"id":"5dfac6cd-ec1e-5d54-98a4-a65cf57457d9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"6d45128d-30db-5879-917a-4a6e682fa7e9","fullItemName":"Management","slug":"management","subChapters":[{"id":"a72789b5-d51e-5516-8ab1-942aae1e0fe8","slug":"uti-no-visible-haematuria-not-pregnant-or-catheterized","fullItemName":"Scenario: UTI  (no visible haematuria, not pregnant or catheterized)"},{"id":"91dbd4da-8761-5e78-9eb2-a773cc7d2764","slug":"uti-with-visible-or-non-visible-haematuria","fullItemName":"Scenario: UTI  with visible or non-visible haematuria"},{"id":"3e093a06-3197-58a5-8c61-94586835adba","slug":"recurrent-uti-no-visible-haematuria-not-pregnant-or-catheterized","fullItemName":"Scenario: Recurrent UTI  (no visible haematuria, not pregnant or catheterized)"},{"id":"09df152e-ea9c-51c1-917c-5c4c01ab2fc8","slug":"uti-in-pregnancy-no-visible-haematuria","fullItemName":"Scenario: UTI in pregnancy  no visible haematuria"},{"id":"6d0e09de-6e28-53df-b01b-55fc899c0dd7","slug":"asymptomatic-bacteriuria-in-pregnancy","fullItemName":"Scenario: Asymptomatic bacteriuria in pregnancy"},{"id":"07efc80a-4963-5037-a8f2-c5b63d298205","slug":"uti-with-catheter-no-haematuria","fullItemName":"Scenario: UTI with catheter  no haematuria"}]},{"id":"7a32c4da-f7b1-5664-92e2-e1fdeca6361a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b42d0bbc-d0ac-52c7-83bf-5fc7a76a38dc","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"76a10025-1806-5d3b-96b0-72401241a768","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"625120b5-8124-549f-b13c-8b37bea158ff","slug":"pivmecillinam","fullItemName":"Pivmecillinam"},{"id":"bae5a7ea-ae42-56ba-82cc-74cbc655059f","slug":"fosfomycin","fullItemName":"Fosfomycin"},{"id":"e8dc8860-ec55-59c6-96c0-805260cb7172","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"e5121975-a684-5651-bf41-c324e815c0f5","slug":"cefalexin","fullItemName":"Cefalexin"}]},{"id":"332fba52-4a32-56f0-b721-29ac73f73e6d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8f34f8fc-4bd2-54e3-87f0-a4a1394f3891","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b392302-d709-5520-a890-25e10021e12b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d4bbe1a-f3f6-523c-85c0-1fae02dd5b27","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"84ca6e0f-7674-5f70-b099-406d5c783d89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4ed139aa-715a-523d-8c0a-8f4e167d29df","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"067e363b-53be-5584-a0e9-2bf38e519877","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"045ecabb-df97-5df3-b561-ecddea4b7b17","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6d45128d-30db-5879-917a-4a6e682fa7e9","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"bc05d1e1-8a31-5898-a7f6-cb34c960ff64","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field a55da46a-36d5-4ea6-a552-a71b00fc1949 --><h3>How should I manage a woman who is not pregnant or catheterized with recurrent urinary tract infection not associated with haematuria?</h3><!-- end field a55da46a-36d5-4ea6-a552-a71b00fc1949 -->","summary":null,"htmlStringContent":"<!-- begin item bde900fd-676e-4ef1-b520-a71b00fc1a64 --><!-- begin field 05d2b948-3ac1-45e4-a0db-a71b00fc1949 --><ul><li><strong>Manage acute UTI</strong> as described in the scenario <a class=\"topic-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/management/uti-no-visible-haematuria-not-pregnant-or-catheterized/#management\">UTI &mdash; (no haematuria, not pregnant or catheterized)</a> ensuring that a urine sample has been sent for culture and sensitivities before antibiotics are started.</li><li><strong>Refer/seek specialist advice on further investigation and management of:</strong><ul><li>Women with recurrent lower UTI where the underlying cause is unknown.</li><li>Women with suspected underlying malignancy — arrange an urgent 2-week wait referral.<ul><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/urological-cancers-recognition-referral/\">Urological cancers - recognition and referral</a> and <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a>.</li></ul></li></ul></li><li><strong>Discuss b</strong><strong>ehavioural and personal hygiene measures, advise the woman to:</strong><ul><li>Avoid douching and occlusive underwear.</li><li>Wipe from front to back after defaecation.</li><li>Avoid delay of habitual and post-coital urination.</li><li>Maintain adequate hydration.</li></ul></li><li><strong>In postmenopausal women consider prescribing vaginal oestrogen </strong>if underlying cause has been investigated and behavioural/hygiene measures alone are ineffective or inappropriate.<ul><li>The lowest effective dose should be prescribed.</li><li>Discuss the risks and benefits of treatment including adverse effects of tenderness and vaginal bleeding (which may require investigation), and the uncertainty of endometrial safety with long-term or repeated use.</li><li>Review treatment within 12 months.</li><li>Do not offer oral oestrogens (hormone replacement therapy) specifically to reduce the risk of recurrent UTI.</li></ul></li><li><strong>Consider antibiotic prophylaxis </strong>if underlying cause has been investigated and behavioural/personal hygiene measures and vaginal oestrogen (in postmenopausal women) are ineffective or inappropriate.<ul><li>Take account of severity and frequency of symptoms, risk of complications, previous urine culture and susceptibility results, previous antibiotic use and the woman’s preference.</li><li>Discuss the risks of long-term antibiotics including resistance and possible adverse effects.</li><li>Ensure that any current UTI has been adequately treated and consider single-dose antibiotic prophylaxis for use when exposed to an identifiable trigger:<ul><li>First choice - Trimethoprim 200mg single dose when exposed to a trigger <em>or</em> Nitrofurantoin (if eGFR ≥45ml/ minute) 100mg single dose when exposed to a trigger.</li><li>Second choice – Amoxicillin 500mg single dose when exposed to a trigger (off label indication) <em>or</em> Cefalexin 500mg single dose when exposed to a trigger.</li></ul></li><li>If there is no improvement after single-dose antibiotic prophylaxis or no identifiable triggers, ensure that any current UTI has been adequately treated then consider a trial of daily antibiotic prophylaxis:<ul><li>First choice - Trimethoprim 100mg at night <em>or</em> Nitrofurantoin (if eGFR ≥45ml/ minute) 50 to 100mg at night</li><li>Second choice – Amoxicillin 250mg at night (off label indication) <em>or</em> Cefalexin 125mg at night</li></ul></li><li>A summary of the National Institute for Health and Care (NICE) <a data-hyperlink-id=\"7d0b518c-c7fc-4aa3-8da5-a9e400e774b3\" href=\"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/antimicrobial-prescribing-guidelines\">antimicrobial prescribing guidance</a> is available on the <a data-hyperlink-id=\"72c0751a-a7a4-467c-980e-a9e400e774d5\" href=\"http://www.nice.org.uk/\">NICE website</a>.</li><li>Arrange follow-up within 3–6 months and advise the woman to seek urgent review if symptoms of acute UTI develop — different antibiotics should be used for prophylaxis and treatment of acute UTI. At follow-up:<ul><li>Check effectiveness of prophylaxis.</li><li>Discuss discontinuation or changing to an alternative (including risk of antimicrobial resistance and adverse effects).</li><li>Reinforce behavioural and personal hygiene measures.</li></ul></li></ul></li></ul><!-- end field 05d2b948-3ac1-45e4-a0db-a71b00fc1949 --><!-- end item bde900fd-676e-4ef1-b520-a71b00fc1a64 -->","subChapters":[{"id":"4d277aa4-1614-5200-8779-7e23a1346f67","slug":"basis-for-recommendation-6ed","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field abfa7d2b-7111-4241-b5af-a71b00fc1949 --><h4>Basis for recommendation</h4><!-- end field abfa7d2b-7111-4241-b5af-a71b00fc1949 -->","summary":null,"htmlStringContent":"<!-- begin item 6ed6c486-6dc9-443b-9885-a71b00fc1949 --><!-- begin field 35e51c42-bed3-4df2-a64d-a71b00fc1949 --><p>The recommendations on management of recurrent lower UTI in women who are not pregnant or catheterised are based on the clinical guidelines <em>Guidance on management of recurrent urinary tract infection in non-pregnant women</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Scottish Medicines Consortium and Scottish Antimicrobial Prescribing Group, 2016</a>], <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2017b</a>], <em>Recurrent Urinary Tract Infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Epp, 2017</a>], <em>Diagnosis of urinary tract infections (UTIs). Quick reference guide for primary care: for consultation and local adaptation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">PHE, 2017</a>], <em>Urological infections </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">EAU, 2018</a>], <em>Recurrent urinary tract infections: antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>], <em>Urinary tract infections (lower): antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018d</a>] and <em>Catheter associated urinary tract infections: antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018c</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Gupta, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Johnston, 2017</a>].</p><h5>Admission</h5><p>Clinical guidelines from Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">PHE, 2017</a>] and the National Institute for Health and Care Excellence (NICE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018d</a>] highlight the importance of prompt recognition and treatment of serious illness such as pyelonephritis and sepsis.</p><h5>Referral to assess for underlying cause</h5><ul><li>Expert opinion in guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Scottish Medicines Consortium and Scottish Antimicrobial Prescribing Group, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">EAU, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Gupta, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BMJ Best Practice, 2018a</a>] is that women with recurrent UTI should be referred for further investigation to identify possible underlying cause such as urinary tract anomalies, malignancy, calculi or fistula.</li><li>The NICE guidance on <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2017b</a>] states that:<ul><li>Suspected bladder cancer should be considered in people aged 60 and over with recurrent or persistent unexplained urinary tract infection.</li><li>Gynaecological malignancy may present with persistent or frequent increased urinary urgency and/or frequency and haematuria.</li></ul></li></ul><h5>Prevention of recurrent UTI</h5><p>The recommendations on prevention of recurrent UTI are based on clinical guidelines from the European Association of Urologists (EAU) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">EAU, 2018</a>] and [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>].</p><ul><li>Any urological risk factors or underlying cause must be identified and treated.</li></ul><p><strong>Self-care and behaviour and personal hygiene measures </strong>— recommendations on behavioural and personal hygiene measures are based on clinical guidelines from the Scottish Medicines Consortium (SMC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Scottish Medicines Consortium and Scottish Antimicrobial Prescribing Group, 2016</a>], NICE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>] and EAU [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">EAU, 2018</a>].</p><ul><li>The NICE guideline committee recognised that although cranberry products are widely used there is only very low quality evidence of benefit in reducing risk of UTIs in non-pregnant women and no evidence to suggest any benefit in older women. The EAU do not recommend cranberry products due to contradictory study results.</li><li>The NICE guideline committee noted evidence (based on 1 small randomized controlled trial) that D-mannose is effective in reducing risk of recurrent UTI in non-pregnant women — the guideline suggests that some non-pregnant women may wish to try D-mannose as a self-care treatment and should be made aware of sugar content.</li></ul><h5>Topical vaginal oestrogen</h5><ul><li>Several clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Epp, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">EAU, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>] recommend a trial of the lowest effective dose of vaginal oestrogen for postmenopausal women with recurrent UTI if behavioural and personal hygiene measures are ineffective or inappropriate.</li><li>Topical vaginal oestrogen can improve vaginal atrophy and increase vaginal lactobacilli which may change vaginal pH suppressing gram negative bacterial growth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Barclay, 2017</a>].</li><li>NICE do not recommend oral oestrogens (HRT) specifically to prevent recurrent UTI in postmenopausal women based on evidence showing a lack of effectiveness and in view of MHRA safety advice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>].</li></ul><h5>Prophylactic antibiotics</h5><ul><li>Clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Epp, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">EAU, 2018</a>] suggest that a trial of prophylactic antibiotics for recurrent UTI (either intermittently following exposure to a trigger [such as sexual intercourse] or daily if no trigger is identified) may be considered <em>only if</em> behavioural and personal hygiene measures, and vaginal oestrogen (in postmenopausal women) are not effective or not appropriate.</li><li>Acute UTI must be fully treated prior to initiation of prophylactic antibiotics (negative culture 1 to 2 weeks after treatment) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Epp, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>].</li><li>A Cochrane systematic review and meta-analysis looking at the efficacy and safety of prophylactic antibiotics in prevention of uncomplicated recurrent UTI in non-pregnant women (n = 19 randomised controlled trials [1120 women] identified an 85% reduction in incidence of symptomatic UTI compared with placebo (relative risk 0.15, 95% CI 0.08–0.28). Side effects included vaginal and oral candidiasis and gastrointestinal symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Albert et al, 2004</a>].</li><li>Prolonged antibiotic use in women may lead to development of resistant organisms after just a few weeks of treatment. A randomised controlled trial (n=252 postmenopausal women) looking at lactobacilli versus antibiotics in prevention of recurrent UTI found where resistance develops it is often to multiple antimicrobial agents and not just the antibiotic that the woman has been prescribed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Beerepoot, 2012</a>].</li><li><strong>Choice and duration of prophylactic antibiotic</strong><ul><li>The recommendations on choice and duration of prophylactic antibiotic are based on the NICE clinical guideline on <em>Urinary tract infection (recurrent): antimicrobial prescribin</em>g [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018b</a>].</li><li>Guidance from the SMC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Scottish Medicines Consortium and Scottish Antimicrobial Prescribing Group, 2016</a>] recommends explaining that antibiotic prophylaxis is not usually a life-long treatment and is given to allow a period of bladder healing making recurrent UTI less likely. SMC recommends that as there is no evidence of additional benefit beyond 6-12 months, ideally treatment should be discontinued after 6 months.</li></ul></li></ul><!-- end field 35e51c42-bed3-4df2-a64d-a71b00fc1949 --><!-- end item 6ed6c486-6dc9-443b-9885-a71b00fc1949 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}